Chris Barron, as Co-Founder and CEO of EMBioSys, leverages over 30 years of extensive experience in the medical device industry to spearhead innovative solutions that address critical healthcare challenges. With a robust background in product development and commercialization, Chris has successfully navigated both early-stage startups...
Chris Barron, as Co-Founder and CEO of EMBioSys, leverages over 30 years of extensive experience in the medical device industry to spearhead innovative solutions that address critical healthcare challenges. With a robust background in product development and commercialization, Chris has successfully navigated both early-stage startups and established companies, demonstrating exceptional leadership and strategic vision. At EMBioSys, he is at the forefront of developing a groundbreaking platform technology that utilizes low-level induced electric fields (iEFs) through non-pharmacological, electrode-free therapeutic wearable garments. This innovative approach aims to meet the pressing medical need for effective treatments for metastatic cancers, with an initial focus on Triple Negative Breast Cancer (TNBC).
Under Chris's guidance, EMBioSys is not only advancing the science of induced electric field therapy but is also committed to ensuring compliance with rigorous industry standards, including ISO 13485. His expertise in medical device product development encompasses a wide array of skills, from engineering management to quality system implementation, ensuring that every product launch is backed by thorough validation and verification (V&V) processes. Chris’s vision for EMBioSys is to revolutionize cancer treatment by providing patients with accessible, wearable solutions that enhance their quality of life while minimizing the side effects commonly associated with traditional therapies. His dedication to innovation and excellence positions EMBioSys as a leader in the medical device sector, paving the way for future advancements in cancer care.
